Triple-negative breast cancer patients with homologous recombination deficiency may benefit from upfront olaparib treatment

Advanced cancer patients given a factor Xa inhibitor during VEGFR–TKI therapy may have a higher risk of bleeding than when given the anticoagulant alone

Patients with recurrent ovarian cancer may benefit from a regimen of pembrolizumab plus bevacizumab and metronomic cyclophosphamide

Data collated from eight studies shows that circulating tumour DNA may predict risk of breast cancer relapse

Fertility preservation is effective in young breast cancer patients without impacting survival

The risk of falls should be considered for active prostate cancer patients beginning androgen receptor inhibitor therapy

Avelumab given after first-line induction chemotherapy does not extend overall survival compared with a continuing chemotherapy regimen for patients with inoperable advanced gastric cancer

Documenting preferred pronouns and identifying interactions between gender-affirming care and cancer treatment could help transgender patients with cancer in the USA